ArticleJournal of thoracic disease2025
Influence of neoadjuvant immunotherapy on surgical approaches in non-small cell lung cancer: insights from a Chinese Expert Questionnaire Survey on Contemporary Practices.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Feasibility of neoadjuvant immunochemotherapy in potentially resectable non-small cell lung cancer: a single-arm meta-analysis.Frontiers in oncology · 2026Pooled it
- Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The extent to which neoadjuvant immunotherapy may complicate subsequent surgical procedures in selected cases of non-small cell lung cancer (NSCLC) is yet to be definitively established. This study was designed to explore the influence of neoadjuvant immunotherapy on the practical surgical management of NSCLC by practicing surgeons. Methods: An electronic survey was methodically disseminated via WeChat groups specifically tailored to thoracic surgeons within China. The data collection encompassed demographic details, management preferences, preoperative assessments, intraoperative techniques, and postoperative outcomes to evaluate variations and challenges in surgical practices following neoadjuvant immunotherapy. Results: The survey garnered 250 valid responses from thoracic surgeons across 25 provinces in China. Stage III central NSCLC was predominantly the context for administering neoadjuvant immunotherapy. The preferred surgical window post-neoadjuvant immunotherapy, as chosen by 81.2% of surgeons, was 4-6 weeks. Notably, 22.4% of the surgeons reported observing immune-related adverse events (irAEs), with a higher incidence noted among the more seasoned practitioners. Views on the technical complexity of surgery post-neoadjuvant immunotherapy were equally varied: 30.0% reported increased difficulty, 33.2% saw no difference, and 28.8% opined that complexity was contingent on the individual case. Conclusions: Within a specialized questionnaire survey targeting thoracic surgeons, perceptions varied regarding the impact of neoadjuvant immunotherapy on surgical outcomes. Overall, neoadjuvant immunotherapy was associated with tolerable adverse events and improved resectability. In this survey, whether neoadjuvant immunotherapy increases the complexity of surgical procedures remained highly contentious, physicians with more experience tended to believe that there was increased irAEs but not much impact on surgical complexity of difficulty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.